Citi analyst Joanne Wuensch lowered the firm’s price target on Insulet to $250 from $260 and keeps a Buy rating on the shares. The analyst revamped the company’s model to include updated revenue and earnings estimates, reflecting changes to new users, market share, and tax rate through 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PODD:
